CDK4 and cancer: Many cancer types are dependent on these activities for growth (Gao et al. 2020), and small molecule CDK4/6 inhibitors are widely studied in clinical trials or have shown success in the treatment of some cancer types (Fassl et al. 2022; Morrison et al. 2024).